AT1001 for the Treatment of COVID-19 Related MIS-C

• ClinicalTrials.gov Identifier: NCT05022303
• Recruitment Status: Recruiting
• First Posted: August 26, 2021
• Last Update Posted: October 11, 2021
• Sponsor: Massachusetts General Hospital
• Information provided by (Responsible Party): Lael Yonker, M.D., Massachusetts General Hospital

Study Description

Brief Summary:

The primary aim of this study is to evaluate the efficacy and safety of AT1001 versus placebo in pediatric patients with SARS-CoV-2 infection who experience early signs of MIS-C and are at high risk of progression.

AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) or matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.

Condition or disease	Intervention/treatment	Phase
Covid19; Multisystem Inflammatory Syndrome in Children	Drug: Larazotide Acetate; Drug: Placebo	Phase 2

Detailed Description:

This is a Phase 2a (Proof of Concept), randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AT1001 for use in hospitalized pediatric patients diagnosed with MIS-C. Eligible participants (N=20) will be treated with AT1001 or matching placebo orally four times a day (QID) for up to 21 days as an add-on to standard of care.

The study includes three phases:

• Screening/Baseline: The main purpose of this phase is to determine if the participant meets entry criterion after obtaining informed consent and obtain baseline assessments.
• Treatment: Eligible participants will be treated with AT1001 or matching placebo 10 μg/kg/dose QID up to 500 μg/dose (rounded to the nearest 50 μg) for 21 days as an add-on to standard of care for MIS-C.
• Follow-up through 24 weeks: The participant will return for a follow-up visits during weekly clinic visits during Week 1 through Week 3, with monthly telemedicine visits at Week 4, Week 8, Week 16 and Week 20, and clinic visits at Week 12 and Week 24.

Safety monitoring, including physical examination, vitals, and clinical laboratory testing will be performed during the screening phase, periodically during treatment phase and at the follow-up phase. Adverse events and concomitant medications will be recorded during the entire study.

Total duration of the participants' participation in the study is approximately 24 weeks (with 21 days treatment period). Total duration of the study is projected to be 12 months, dependent on enrollment timeline.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Placebo and drug arm (10 μg/kg/dose up to 500 μg/dose)
• Masking: Double (Participant, Investigator)
• Masking Description: Participant and investigator blinded, Pharmacy unblinded.
• Primary Purpose: Treatment
• Official Title: A Phase 2a (Proof of Concept), Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AT1001 for the Treatment of COVID-19 Related Multisystem Inflammatory Syndrome in Children (MIS-C)
• Estimated Study Start Date: October 2021
• Estimated Primary Completion Date: September 2022
• Estimated Study Completion Date: December 2022

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo; Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.	Drug: Placebo; Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
Experimental: Larazotide Acetate; AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.	Drug: Larazotide Acetate; AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.; Other Name: AT1001

Outcome Measures

Primary Outcome Measures :

1. Evaluate the efficacy and safety of AT1001 versus placebo on mitigating symptoms of MIS-C [ Time Frame: 24 weeks ]
   • To evaluate the efficacy and safety of AT1001 versus placebo in pediatric patients with SARS-CoV-2 infection who experience early signs of MIS-C and are at high risk of progression.
2. Determine proportion of participants with improvement in MIS-C related GI symptoms and no progression of disease [ Time Frame: 24 weeks ]

   Improvement in GI symptoms is defined as:

   • Improvement in PedsQL GI Symptoms Scales score ≥48 hours, as determined by patient or caregiver response.
   • AND improvement in clinical manifestation of GI symptoms, as documented by complete physical exam or clinical assessment and clinical laboratory tests or imaging.

   No Progression of MIS-C is defined as:

   • No involvement of additional organ involvement, as identified by clinical assessment and clinical laboratory tests or imaging.
   • AND no new onset of new or worsening GI symptoms for ≥48 hours including nausea, vomiting, diarrhea, loss of appetite, and/or abdominal pain, as determined by patient or caregiver symptom report or worsening PedsQL GI Symptoms Scales scores.

Secondary Outcome Measures :

1. Determine the impact of AT1001 on infectious and inflammatory markers of MIS-C [ Time Frame: 24 weeks ]
   Secondary aims of this study include determining the impact of AT1001 on infectious and inflammatory markers of MIS-C.
2. Determine the impact of AT1001 on improvement in MIS-C symptoms for ≥48 hours, as determined by patient or caregiver symptom report on MIS-C Symptom Questionnaire. [ Time Frame: 24 weeks ]
3. Determine the impact of AT1001 on length of stay in hospital (days from baseline to readiness to discharge). [ Time Frame: 24 weeks ]
4. Determine the impact of AT1001 on re-presentation to medical care for MISC-related symptoms after discharge. [ Time Frame: 24 weeks ]
5. Determine the impact of AT1001 on need for escalation of care (eg, transfer from hospital ward to ICU; supplemental oxygen; mechanical ventilation). [ Time Frame: 24 weeks ]
6. Determine the impact of AT1001 on change from baseline in additional organ system(s) involvement during acute presentation/hospitalization, as identified by clinical assessment and clinical laboratory tests. [ Time Frame: 24 weeks ]
7. Determine the impact of AT1001 on change from baseline in levels of IgM, IgG, and IgA antibodies against SARS CoV-2. [ Time Frame: 24 weeks ]
8. Determine the impact of AT1001 on change from baseline in levels of inflammatory markers (CRP, d-dimer, ferritin). [ Time Frame: 24 weeks ]
9. Determine the impact of AT1001 on normalization of SARS-CoV-2 Spike, S1 and nucleocapsid. [ Time Frame: 24 weeks ]
10. Determine the impact of AT1001 on change from baseline in levels of zonulin. [ Time Frame: 24 weeks ]
11. Determine the impact of AT1001 on change in mortality (all causes) [ Time Frame: 24 weeks ]

Eligibility Criteria

• Ages Eligible for Study: 1 Month to 21 Years (Child, Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Pediatric patients with or without comorbidity
2. Age ≥ 1 month to < 21 years

3. Confirmed MIS-C by signs and symptoms as detailed by the CDC Health Advisory (https://www.cdc.gov/mis-c/hcp/; May 14, 2020)

   1. Persistent fever/chills (>38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours); AND
   2. One or more laboratory parameters (evidence of inflammation); AND,

   i) elevated C-reactive protein (CRP) ii) elevated erythrocyte sedimentation rate (ESR) iii) elevated ferritin iv) elevated lactic acid dehydrogenase (LDH) v) elevated d-dimer vi) elevated fibrinogen vii) elevated procalcitonin viii) elevated interleukin 6 (IL-6) ix) increased neutrophils x) reduced lymphocytes xi) low albumin c) Evidence of clinically severe illness requiring hospitalization, with multisystem (>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological)-MUST include GI symptoms, such as nausea, vomiting, diarrhea and/or abdominal pain; AND, d) No alternative plausible diagnoses; AND e) Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test

4. Subject (or legal authorized representative) capable of understanding and signing an informed consent form and assent form, when appropriate.

Exclusion Criteria:

1. Female participants pregnant and/or lactating.
2. Female participant has childbearing potential and is unwilling to use an acceptable method of birth control for the duration of the study.
3. Participant has a significant co-morbid disease that by the Investigator's determination would make the participant unsuitable for enrollment, including unstable medical conditions.
4. Participation in any other clinical investigation using an experimental drug within 30 days prior to screening or intends to participate in another clinical study while participating in AT1001 MIS-C 101 study.
5. Have participated in a blood/plasma donation or blood loss greater than 400 mL within 90 days, or greater than 200 mL within 30 days prior to Screening.
6. Known hypersensitivity to any of the formulation components of AT1001.

Contacts and Locations

Contacts

Contact: Lael Yonker, MD; 617-726-8707; lyonker@mgh.harvard.edu

Contact: Victoria A Kenyon, BA; 617-643-4366; vakenyon@partners.org

Locations

United States, Massachusetts

Massachusetts General Hospital; Recruiting

Boston, Massachusetts, United States, 02114

Contact: Lael Yonker, MD 617-726-8707 LYONKER@MGH.HARVARD.EDU

Sponsors and Collaborators

Massachusetts General Hospital

More Information

• Responsible Party: Lael Yonker, M.D., Pulmonary Attending Physician, Massachusetts General Hospital
• ClinicalTrials.gov Identifier: NCT05022303
• Other Study ID Numbers: 2021P002143
• First Posted: August 26, 2021
• Last Update Posted: October 11, 2021
• Last Verified: October 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

COVID-19; Syndrome; Disease; Pathologic Processes; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases